We are developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, and which have pharmacological and pharmacokinetic properties that may also address vulnerable patients:

• TRX01 (ratutrelvir): Mpro/3CL inhibitor in development for treatment of COVID19

• TRX100 (tivoxavir marboxil): Cap-independent endonuclease inhibitor in development for treatment of [pandemic] influenza

Our product candidates, designed for targeting cancer, are derived from a novel chemistry platform supported by artificial intelligence and machine learning approaches, which together define our discovery approach. Compounds are optimized through guided medicinal chemistry, with the goal of developing effective therapies and avoiding unpleasant side-effects.

• Narazaciclib: investigational, proprietary, targeted multi-kinase CDK4-plus inhibitor narazaciclib is being evaluated in dose ranging Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole, with the aim to define the recommended phase 2 dose for further development in metastatic breast, endometrial and potentially other cancers. Pre-clinically narazaciclib has shown activity in breast cancer cells resistant to palbociclib, assumed due to targeting proteins such as CSF-1 and FGFR implicated in resistance to these agents. Targeting ARK-5 (also known as NUAC 1) suggests additional tumors can be studied when high expression of these proteins is correlated with resistance.